Available now: free lab and office space in the Lab Hotel Read more
Achilles Therapeutics Doses First Patient with Higher-dose cNeT in Phase I/IIa CHIRON Trial in Advanced NSCLC and Initiates Enrollment in Cohort B of the THETIS Trial (cNeT + PD-1 checkpoint inhibitor) in Metastatic Malignant Melanoma
Published on 9 May 2022
Exploristics KerusCloud Spring 2022 Launches
Published on 5 May 2022
Achilles Therapeutics Appoints Bernhard Ehmer to Board of Directors
Published on 4 May 2022
CGT Catapult works closely with NHS through Accelerated Access Collaborative to offer pioneering cell and gene treatments
Published on 4 May 2022
Quell Therapeutics and Cellistic™ enter a strategic collaboration to develop an iPSC-derived allogeneic T-regulatory (Treg) cell therapy platform
Published on 27 Apr 2022
Galecto Completes Enrollment in Global Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of IPF
Published on 26 Apr 2022
Cytiva wins double at Asia-Pacific Bioprocessing Excellence Awards
Published on 21 Apr 2022
Freeline Appoints Paul Schneider as Chief Financial Officer
Published on 19 Apr 2022
Achilles Therapeutics Announces Manufacturing Expansion in the UK and Partnership for Manufacturing in the US
Published on 12 Apr 2022
Pharmidex are delighted to be one of sixteen partners in an EU Horizon 2020 grant - HeatNMof
Published on 12 Apr 2022
Pfizer to Acquire ReViral and Its Respiratory Syncytial Virus Therapeutic Candidates
Published on 7 Apr 2022
Autolus Therapeutics Receives EMA Orphan Medical Product Designation for obe-cel for Treatment of Acute Lymphoblastic Leukemia
Published on 31 Mar 2022
Cell and Gene Therapy Catapult: Symbiosis announces successful completion of UK Research and Innovation (UKRI) project, which will enhance the manufacturing supply chain for ATMPs within the UK
Published on 30 Mar 2022
Galecto Completes Enrollment in Phase 1b/2a GULLIVER-2 Trial of its Selective, Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis
Published on 29 Mar 2022
CGT Catapult publishes National Cell and Gene Therapy Vision for the UK as it hosts its fourth annual clinical adoption workshop
Published on 24 Mar 2022
Freeline Announces Updated Development Plan and Timelines for FLT190 for People with Fabry Disease
Published on 24 Mar 2022
Cell And Gene Therapy Catapult Launches 2021 Clinical Trials Database Report
Published on 22 Mar 2022
UKRI strategy will keep UK at forefront of research and innovation
Published on 17 Mar 2022
Freeline Closes $26.1 Million Registered Direct Offering of American Depositary Shares
Published on 15 Mar 2022
Free lab and office space available in the Lab Hotel at Stevenage Bioscience Catalyst
Published on 11 Mar 2022
Exploristics awarded Silver Diversity Charter Mark
Published on 9 Mar 2022

Copyright © 2022 Stevenage Bioscience Catalyst

Designed and built by Onespacemedia

We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.